Hepatitis C: The role of new interferons in the era of STAT-C. Nature reviews. Gastroenterology & hepatology [Nat Rev Gastroenterol Hepatol] Journal article

More than 50% of patients infected with HCV genotype 1 fail respond to standard treatment with peginterferon plus ribavirin. potent treatment strategies are urgently needed to improve outcomes for such patients. novel interferons and specifically targeted antiviral therapy for HCV (STAT-C) represent promising strategies.

Nature reviews. Gastroenterology & hepatology [Nat Rev Gastroenterol Hepatol]